ReCor Medical snags CE mark for next-gen renal denervation

Now that Boston Scientific ($BSX) has purchased Vessix Vascular, California's ReCor Medical is the only privately held company with a CE marked renal denervation device. Now the company is upping the ante, getting European approval for a second generation of its ultrasound-powered Paradise. The new Paradise works faster than its predecessor thanks to an improved cooling technology, the company says, and ReCor remains the only player in the renal denervation space that uses ultrasound over radiofrequency to deaden nerves and reduce blood pressure. More

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.